• Nausea

Cinvanti Generic Name & Formulations

General Description

Aprepitant 130mg/18mL; emulsion for IV inj or infusion after dilution; contains egg lecithin, ethanol.

Pharmacological Class

Substance P/NK1 receptor antagonist.

How Supplied

Single-dose vial—1


Generic Availability


Cinvanti Indications


In combination with other antiemetic agents to prevent acute and delayed nausea and vomiting associated with initial and repeat courses of moderately to highly emetogenic cancer chemotherapy, including high-dose cisplatin.

Limitations of Use

Not studied for treating established nausea and vomiting.

Cinvanti Dosage and Administration


Give with dexamethasone and 5-HT3 antagonist (see full labeling). Administer approx. 30mins prior to chemotherapy. Give by IV inj over 2mins (do not dilute) or by IV infusion over 30mins. Moderately emetogenic (3-day regimen): 100mg IV on Day 1, then oral aprepitant 80mg on Days 2 and 3. Moderately to highly emetogenic (single-dose regimen): 130mg IV on Day 1.


Not established.

Cinvanti Contraindications


Concomitant pimozide.

Cinvanti Boxed Warnings

Not Applicable

Cinvanti Warnings/Precautions


Monitor for hypersensitivity reactions; discontinue and treat appropriately if occur; do not reinitiate if symptoms experienced with previous use. Severe hepatic impairment: monitor. Elderly. Pregnancy: avoid. Nursing mothers.

Cinvanti Pharmacokinetics

See Literature

Cinvanti Interactions


See Contraindications. Monitor concomitant CYP3A4 substrates, including chemotherapy agents (eg, ifosfamide, vinblastine, vincristine). Avoid concomitant moderate-to-strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir, diltiazem) or strong CYP3A4 inducers (eg, carbamazepine, phenytoin, rifampin). Potentiates dexamethasone (reduce its oral dose by 50%), methylprednisolone (reduce its IV dose by 25% and its oral dose by 50%), midazolam, alprazolam, triazolam. May antagonize warfarin (closely monitor INR for 2 weeks after starting each cycle), other CYP2C9 substrates, oral contraceptives (use alternative or backup methods during and for 1 month after last dose).

Cinvanti Adverse Reactions

Adverse Reactions

Headache, fatigue, eructation, infusion-site reactions; anaphylaxis.

Cinvanti Clinical Trials

See Literature

Cinvanti Note

Not Applicable

Cinvanti Patient Counseling

See Literature